Polyacrylate–Peptide Antigen Conjugate as a Single-Dose Oral Vaccine against Group A <i>Streptococcus</i>

• Main Authors: Mohammad Omer Faruck, Lili Zhao, Waleed M. Hussein, Zeinab G. Khalil, Robert J. Capon, Mariusz Skwarczynski, Istvan Toth
• Format: Article
• Language: English
• Published: MDPI AG 2020-01-01
• Series: Vaccines
• Subjects: peptide vaccine; poly (methyl acrylate); oral delivery; nanoparticles; polymer–peptide conjugate; group a <i>streptococcus</i>
• Online Access: https://www.mdpi.com/2076-393X/8/1/23

Group A <i>Streptococcus</i> (GAS)-associated rheumatic heart disease is a leading cause of death caused by GAS infection. While antibiotics can treat the infection in most cases, growing antibiotic resistance, late medical intervention, and recurrent infection are major obstacles to the effective treatment of GAS-associated diseases. As GAS infection typically originates from the bacterial colonization of mucosal tissue in the throat, an oral vaccine that can generate both systemic and mucosal immune responses would solve problems associated with traditional medical interventions. Moreover, orally delivered vaccines are more easily administered and less expensive for mass immunization. In this study, the B-cell epitope J8, derived from GAS M protein, and universal T-helper Pan HLA-DR-binding epitope peptide (PADRE), were conjugated to poly (methyl acrylate) (PMA) to form a self-assembled nanoparticle vaccine candidate (PMA-P-J8). Strong systemic and mucosal immune responses were induced upon single oral immunization of mice with the conjugate. The antibodies generated were opsonic against GAS clinical isolates as measured after boost immunization. Thus, we developed a simple conjugate as an effective, adjuvant-free oral peptide-based vaccine.